These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27886820)

  • 1. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Majithia A; Bhatt DL
    Interv Cardiol Clin; 2017 Jan; 6(1):25-37. PubMed ID: 27886820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies.
    Bundhun PK; Yanamala CM; Huang F
    BMC Cardiovasc Disord; 2016 Aug; 16(1):161. PubMed ID: 27577530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review.
    Elliott J; Kelly SE; Bai Z; Liu W; Skidmore B; Boucher M; So DY; Wells GA
    BMJ Open; 2017 Apr; 7(4):e015421. PubMed ID: 28377396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial.
    Lemmert ME; Oldroyd K; Barragan P; Lesiak M; Byrne RA; Merkulov E; Daemen J; Onuma Y; Witberg K; van Geuns RJ
    Am Heart J; 2017 May; 187():104-111. PubMed ID: 28454794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
    Chen H; Power D; Giustino G
    Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.
    Cho MS; Park DW
    Korean J Intern Med; 2017 Sep; 32(5):769-779. PubMed ID: 28823143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
    Franzone A; Piccolo R; Gargiulo G; Ariotti S; Marino M; Santucci A; Baldo A; Magnani G; Moschovitis A; Windecker S; Valgimigli M
    JAMA Cardiol; 2016 Oct; 1(7):795-803. PubMed ID: 27572001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Tada T; King LA; Kastrati A
    Eur Heart J; 2012 Dec; 33(24):3078-87. PubMed ID: 23091199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
    Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
    Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis.
    Spencer FA; Prasad M; Vandvik PO; Chetan D; Zhou Q; Guyatt G
    Ann Intern Med; 2015 Jul; 163(2):118-26. PubMed ID: 26005909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence.
    Palmerini T; Stone GW
    Eur Heart J; 2016 Jan; 37(4):353-64. PubMed ID: 26795933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
    Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
    Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ndrepepa G; Schunkert H; Fusaro M; Kastrati A
    Clin Res Cardiol; 2015 Oct; 104(10):887-901. PubMed ID: 25903112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
    Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.